The fourth international conference on malignant lymphoma

1991 ◽  
pp. 3-6
Author(s):  
Brian L. Samuels ◽  
John E. Ultmann
Keyword(s):  
Malignant Lymphoma ◽  
International Conference

11. International Conference on Malignant Lymphoma: Neue Therapieoptionen bei B- und T-Zell-Lymphomen

2011 ◽  
Vol 02 (04) ◽  
pp. 164-165
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Malignant Lymphoma ◽  
International Conference

Die auf dem 11. ICML-Kongress vorgestellten Studiendaten zeigen für Lenalidomid (Revlimid®)* eine wichtige Rolle bei der Entwicklung neuer Behandlungsoptionen jenseits der Chemotherapie beim diffus großzelligen B-Zell-Lymphom (DLBCL) als auch beim indolenten B-Zell NHL-Lymphom. Als neue Therapieoption bei peripheren T-Zell-Lymphomen (PTCL) werden auch die Histon-Deacetylase (HDAC)-Hemmer wie Romidepsin steigende Bedeutung erhalten, meinte Prof. Bertrand Coiffier, Lyon/Frankreich, von der renommierten GELA-Studiengruppe.

scholarly journals The fourth international conference on malignant lymphoma

1991 ◽  
Vol 2 ◽  
pp. 1-7
Author(s):  
Brian L. Samuels ◽  
John E. Ultmann
Keyword(s):  
Malignant Lymphoma ◽  
International Conference

scholarly journals Report of the 14th International Conference on Malignant Lymphoma (ICML) Closed Workshop on Future Design of Clinical Trials in Lymphomas

2018 ◽  
Vol 24 (13) ◽  
pp. 2993-2998 ◽  
Author(s):  
Anastasios Stathis ◽  
Alexia Iasonos ◽  
John F. Seymour ◽  
Catherine Thieblemont ◽  
Vincent Ribrag ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Malignant Lymphoma ◽  
International Conference ◽  
Future Design

scholarly journals Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

2014 ◽  
Vol 32 (27) ◽  
pp. 3059-3067 ◽  
Author(s):  
Bruce D. Cheson ◽  
Richard I. Fisher ◽  
Sally F. Barrington ◽  
Franco Cavalli ◽  
Lawrence H. Schwartz ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Malignant Lymphoma ◽  
Hodgkin Lymphoma ◽  
Response Assessment ◽  
Disease Extent ◽  
Single Node ◽  
Bulky Disease ◽  
International Conference ◽  
Non Hodgkin Lymphoma ◽  
Positron Emission

The purpose of this work was to modernize recommendations for evaluation, staging, and response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). A workshop was held at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland, in June 2011, that included leading hematologists, oncologists, radiation oncologists, pathologists, radiologists, and nuclear medicine physicians, representing major international lymphoma clinical trials groups and cancer centers. Clinical and imaging subcommittees presented their conclusions at a subsequent workshop at the 12th International Conference on Malignant Lymphoma, leading to revised criteria for staging and of the International Working Group Guidelines of 2007 for response. As a result, fluorodeoxyglucose (FDG) positron emission tomography (PET)–computed tomography (CT) was formally incorporated into standard staging for FDG-avid lymphomas. A modification of the Ann Arbor descriptive terminology will be used for anatomic distribution of disease extent, but the suffixes A or B for symptoms will only be included for HL. A bone marrow biopsy is no longer indicated for the routine staging of HL and most diffuse large B-cell lymphomas. However, regardless of stage, general practice is to treat patients based on limited (stages I and II, nonbulky) or advanced (stage III or IV) disease, with stage II bulky disease considered as limited or advanced disease based on histology and a number of prognostic factors. PET-CT will be used to assess response in FDG-avid histologies using the 5-point scale. The product of the perpendicular diameters of a single node can be used to identify progressive disease. Routine surveillance scans are discouraged. These recommendations should improve evaluation of patients with lymphoma and enhance the ability to compare outcomes of clinical trials.

Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002

2003 ◽  
Vol 21 (12) ◽  
pp. 2407-2414 ◽  
Author(s):  
Andrés J.M. Ferreri ◽  
Lauren E. Abrey ◽  
Jean-Yves Blay ◽  
Bettina Borisch ◽  
Jacob Hochman ◽  
...  
Keyword(s):  
Malignant Lymphoma ◽  
Current Knowledge ◽  
Scientific Information ◽  
Primary Cns Lymphoma ◽  
Collaborative Group ◽  
Cns Lymphoma ◽  
Future Studies ◽  
International Conference ◽  
Group A ◽  
Lymphoma Study Group

Under the sponsorship of the International Extranodal Lymphoma Study Group, a Multidisciplinary Workshop on primary CNS lymphoma (PCNSL) with over 50 participants from Europe, North America, Israel, and Australia was held as part of the Eighth International Conference on Malignant Lymphoma in Lugano, Switzerland (June 12 to 15, 2002). The main purposes of the Workshop were to exchange the latest scientific information, to analyze methodologic issues in the design of clinical trials, to reach a consensus on treatment recommendations and prognostic factors, to discuss clinical and molecular targets for future studies, and to establish an international collaborative group to conduct laboratory and clinical investigations in PCNSL. This article summarizes the contents of the Workshop, analyzes the current knowledge on the most relevant biologic and clinical issues in PCNSL, and focuses on fundamental challenges to be addressed in future studies.

Sign in / Sign up

Export Citation Format

Share Document